Cortical interneurons are inhibitory neurons that comprise approximately 20-30% of the cortical neuron population and play essential roles in regulating cortical circuit activity[1]. In Alzheimer's disease (AD), these neurons undergo significant pathological changes that contribute to network hyperexcitability, seizures, and cognitive impairment[2]. This page details the specific interneuron subtypes affected in AD, the molecular mechanisms underlying their dysfunction, and therapeutic approaches targeting interneuron circuits.
Cortical interneurons are diverse inhibitory neurons that modulate cortical processing through precise temporal and spatial control of excitatory pyramidal neuron activity[3]. Their functions include:
The major cortical interneuron subclasses include parvalbumin (PV)-positive cells, somatostatin (SST)-positive cells, and vasoactive intestinal peptide (VIP)-positive cells, each with distinct morphological, electrophysiological, and molecular properties[4].
PV interneurons are fast-spiking cells that provide powerful perisomatic inhibition to pyramidal neurons[5]. In AD:
SST interneurons provide dendritic inhibition and regulate synaptic plasticity[9]. In AD:
VIP interneurons primarily target other interneurons, providing disinhibition[11]. In AD:
Tau protein pathology directly affects interneurons[12]:
Aβ oligomers impact interneuron function[13]:
Network-level consequences include[14]:
Pharmacological strategies include[15]:
Emerging approaches:
Managing hyperexcitability[17]:
Interneuron dysfunction directly affects cognition[18]:
AD patients have 6-10x increased seizure risk[19]:
Early intervention: Monitoring for subclinical seizures
Anti-epileptic selection: Drug interactions with AD medications
Lifestyle modifications: Sleep, stress reduction
Parvalbumin Interneurons
Somatostatin Interneurons
VIP Interneurons
Cortical Neurons in Alzheimer's Disease
Chandelier Cells
Basket Cells
Tau Pathology Amyloid Cascade Hypothesis
Network Hyperexcitability in AD
GABA Signaling Pathway
Hensch, Parvalbumin interneurons in neural circuits (2005). Neuroscience. 2005. ↩︎
Palop & Mucke, Network dysfunction in Alzheimer's disease (2016). Nature Neuroscience. 2016. ↩︎
Rudy et al. Diversity and functions of cortical interneurons (2011). Hippocampus. 2011. ↩︎
Tremblay et al. GABAergic interneurons in brain disorders (2016). Neuropharmacology. 2016. ↩︎
Hu et al. Parvalbumin-positive interneurons in brain function (2014). Trends in Cognitive Sciences. 2014. ↩︎
Brendel et al. Reduction of PV neurons in AD (2017). Neurobiology of Aging. 2017. ↩︎
Kowalski et al. Tau pathology in PV neurons in AD (2020). Acta Neuropathologica. 2020. ↩︎
Verret et al. Gamma oscillations and AD (2012). Cell. 2012. ↩︎
Urban-Ciecko & Barth, Somatostatin and memory (2016). Trends in Cognitive Sciences. 2016. ↩︎
Lei et al. SST interneuron dysfunction in AD models (2017). Nature Neuroscience. 2017. ↩︎
Pi et al. VIP neurons and disinhibition (2013). Trends in Cognitive Sciences. 2013. ↩︎
Hall et al. Tau and interneurons (2018). Brain Pathology. 2018. ↩︎
Mucke & Selkoe, Neurotoxicity of amyloid-beta (2012). Cold Spring Harbor Perspectives in Medicine. 2012. ↩︎
Palop et al. Aberrant excitatory networks in AD (2011). Nature Neuroscience. 2011. ↩︎
Amaral et al. GABAergic therapies for AD (2018). Journal of Alzheimer's Disease. 2018. ↩︎
Tong et al. Interneuron transplantation (2014). Nature Neuroscience. 2014. ↩︎
Vossel et al. Seizures and AD (2017). Brain. 2017. ↩︎
Mably et al. Gamma oscillations and memory (2017). Trends in Cognitive Sciences. 2017. ↩︎
Vossel et al. Seizure incidence in AD (2013). JAMA Neurology. 2013. ↩︎